Karin Kozbial 1 , Stephan Moser 2 , Ramona Al - Zoairy 3 , Remy Schwarzer 4 , Christian Datz 5 , Rudolf Stauber 6 , Hermann Laferl 7 , Michael Strasser 8 , S andra Beinhardt 1 , Albert Friedrich Stättermayer 1 , Michael Gschwantler 2 , H einz Zoller 3 , Andreas Maieron 4 ,9 , Ivo Graziadei 10 , Michael Trauner 1 , P etra Steindl - Munda 1 , Harald Hofer 1, 11 , P eter Ferenci
doi: 10.1111/liv.13629
Link To Article: https://jumpshare.com/v/HPTaAyMtTjxr5Wd8brk1
*Article downloaded and shared by Henry E. Chang today on Twitter.
Key points
doi: 10.1111/liv.13629
Link To Article: https://jumpshare.com/v/HPTaAyMtTjxr5Wd8brk1
*Article downloaded and shared by Henry E. Chang today on Twitter.
Key points
SVR is durable irrespective of the interferon - free DAA regimen used.
Survival was excellent for patients with F3 and Child - Pugh A cirrhosis.
Decompensation before or at baseline was significantly associated with decompensation and with death during follow-up .
Despite successful therapy a risk of hepatocellular carcinoma remains among patients with cirrhosis, necessitating a regular follow-up
Survival was excellent for patients with F3 and Child - Pugh A cirrhosis.
Decompensation before or at baseline was significantly associated with decompensation and with death during follow-up .
Despite successful therapy a risk of hepatocellular carcinoma remains among patients with cirrhosis, necessitating a regular follow-up
No comments:
Post a Comment